Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.

The tolerability and efficacy of four courses of paclitaxel and ifosfamide plus cisplatin every 3 weeks was evaluated in patients with residual or refractory ovarian cancer. Additionally, supportive haematological effects of recombinant human interleukin 3 (rhIL-3) and recombinant human granulocyte...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Veldhuis, G. J., Willemse, P. H., Beijnen, J. H., Boonstra, H., Piersma, H., van der Graaf, W. T., de Vries, E. G.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group|1 1997
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2063352/
https://ncbi.nlm.nih.gov/pubmed/9043028
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares